Quoin Pharmaceuticals Ltd Stock Fundamentals

QNRX Stock  USD 0.30  0.01  3.45%   
Quoin Pharmaceuticals Ltd fundamentals help investors to digest information that contributes to Quoin Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Quoin Stock. The fundamental analysis module provides a way to measure Quoin Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quoin Pharmaceuticals stock.
At this time, Quoin Pharmaceuticals' Research Development is fairly stable compared to the past year. Net Interest Income is likely to rise to about 744.6 K in 2025, whereas Selling General Administrative is likely to drop slightly above 4 M in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Quoin Pharmaceuticals Ltd Company Return On Equity Analysis

Quoin Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Quoin Pharmaceuticals Return On Equity

    
  -1.35  
Most of Quoin Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quoin Pharmaceuticals Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Quoin Total Stockholder Equity

Total Stockholder Equity

6.62 Million

At this time, Quoin Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year.
Based on the latest financial disclosure, Quoin Pharmaceuticals Ltd has a Return On Equity of -1.3537. This is 94.35% lower than that of the Biotechnology sector and 96.29% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Quoin Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Quoin Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Quoin Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quoin Pharmaceuticals competition to find correlations between indicators driving Quoin Pharmaceuticals's intrinsic value. More Info.
Quoin Pharmaceuticals Ltd is rated fifth in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Quoin Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quoin Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Quoin Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quoin Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quoin Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Quoin Pharmaceuticals by comparing valuation metrics of similar companies.
Quoin Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Quoin Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Quoin Pharmaceuticals from analyzing Quoin Pharmaceuticals' financial statements. These drivers represent accounts that assess Quoin Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Quoin Pharmaceuticals' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap13.6M4.7M6.9M4.4M3.1M2.9M
Enterprise Value8.8M(210.7K)4.0M2.0M(3.6B)(3.4B)

Quoin Fundamentals

About Quoin Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Quoin Pharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quoin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quoin Pharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue(690.00)(724.50)
Cost Of Revenue93.1 K102.9 K
Sales General And Administrative To Revenue(25.61)(26.89)
Research And Ddevelopement To Revenue(26.54)(27.86)
Capex To Revenue(0.59)(0.62)
Revenue Per Share(116.82)(122.66)
Ebit Per Revenue(49.23)(51.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.